News Detail

Virax Biolabs FY26 net loss narrows to $5.03 million; revenue more than doubled to $12,423

PUBT · 3d ago

Listen to the news

Virax Biolabs FY26 net loss narrows to $5.03 million; revenue more than doubled to $12,423

Virax Biolabs posted a net loss of USD 5.03 million, narrowing from USD 6.07 million a year earlier.
Operating loss widened to USD 6.4 million from USD 6.08 million, while revenue more than doubled to USD 12,423.
Research and development expense climbed to USD 3.74 million from USD 2.03 million, while general and administrative costs fell to USD 2.67 million from USD 3.99 million.
Income tax benefit rose to USD 900,240 from USD 136,661, reflecting research and development tax credits.
Cash ended the year at USD 6.44 million, up from USD 4.23 million, as financing inflows increased to USD 7.09 million from USD 5.81 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-295158), on July 06, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.